CoreCap Advisors’s Janux Therapeutics JANX Stock Holding History

CoreCap Advisors’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-9	Closed	-$482	–	3230
2024 Q4	$482	Buy	+9	New	+$476	﹤0.01%	2524

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

CoreCap Advisors's JANX Position: Q1 2025 in Review

CoreCap Advisors sold out of Janux Therapeutics (JANX) in Q1 2025, closing a stake of 9 shares — an estimated $482 sold.

CoreCap Advisors first reported a position in JANX in Q4 2024 and held it in 1 quarter. The position peaked at $482 in Q4 2024. 181 funds tracked by Wall St. Rank hold JANX as of Q1 2025.

CoreCap Advisors reported no remaining Janux Therapeutics position as of Q1 2025 after selling out during the quarter.
CoreCap Advisors sold 9 Janux Therapeutics shares in Q1 2025, an estimated $482.
CoreCap Advisors first reported a position in Janux Therapeutics in Q4 2024 and held it in 1 quarter.
CoreCap Advisors's Janux Therapeutics position peaked at $482 in Q4 2024.
181 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2025.

Based on CoreCap Advisors's 13F filing for Q1 2025, filed 9 May 2025.